These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25677328)

  • 1. Response to letter by Dr. Engel.
    Rauck RL
    Pain Med; 2015 Feb; 16(2):404-6. PubMed ID: 25677328
    [No Abstract]   [Full Text] [Related]  

  • 2. All failures count.
    Engel A
    Pain Med; 2015 Feb; 16(2):404. PubMed ID: 25530072
    [No Abstract]   [Full Text] [Related]  

  • 3. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study.
    Rauck RL; Nalamachu S; Wild JE; Walker GS; Robinson CY; Davis CS; Farr SJ
    Pain Med; 2014 Jun; 15(6):975-85. PubMed ID: 24517082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of cigarette smoking on hydrocodone efficacy in chronic pain patients.
    Ackerman WE
    J Ark Med Soc; 2012 Oct; 109(5):90-3. PubMed ID: 23061240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain.
    Hale ME; Zimmerman TR; Eyal E; Malamut R
    J Opioid Manag; 2015; 11(6):507-18. PubMed ID: 26728648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
    Hale ME; Ma Y; Malamut R
    J Opioid Manag; 2016; 12(2):139-47. PubMed ID: 27194199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Analysis of Rescue Medication Utilization from a 3-Month, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Chronic Low Back Pain Treated with Single-Entity, Twice-Daily, Extended-Release Hydrocodone.
    Nalamachu S; deLeon-Casasola OA; Robinson CY; Galer BS; Gould E; Gammaitoni A
    Pain Med; 2015 Dec; 16(12):2338-43. PubMed ID: 26301791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical Studies.
    Campbell K; Kutz JW; Shoup A; Wen W; Lynch SY; He E; Ripa SR
    Pain Physician; 2017; 20(1):E183-E193. PubMed ID: 28072811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioids in chronic pain: evolving best practice strategies. Introduction.
    Gloth FM
    Am J Med; 2013 Mar; 126(3 Suppl 1):S1-2. PubMed ID: 23219043
    [No Abstract]   [Full Text] [Related]  

  • 10. Chronic pain, addiction, and Zohydro.
    Olsen Y; Sharfstein JM
    N Engl J Med; 2014 May; 370(22):2061-3. PubMed ID: 24758596
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain.
    Bartoli A; Michna E; He E; Wen W
    Postgrad Med; 2015 Jan; 127(1):5-12. PubMed ID: 25526227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine Drug Screens to Monitor Opioid Use for Managing Chronic Pain.
    Haymond S; Nagpal G; Heiman H
    JAMA; 2017 Sep; 318(11):1061-1062. PubMed ID: 28975284
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain.
    Taber L; Lynch SY; He E; Ripa SR
    Postgrad Med; 2016 Jan; 128(1):23-33. PubMed ID: 26681111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic evaluation of hydrocodone/acetaminophen for pain management.
    Singla A; Sloan P
    J Opioid Manag; 2013; 9(1):71-80. PubMed ID: 23709306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to set boundaries with chronic pain patients.
    Cosio D
    J Fam Pract; 2014 Mar; 63(3 Suppl):S3-8. PubMed ID: 24701609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Abuse-Deterrence Technology: A 12-month Open-label Study in Patients with Chronic Pain.
    Hale ME; Zimmerman TR; Ma Y; Malamut R
    Pain Pract; 2017 Feb; 17(2):229-238. PubMed ID: 26857424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain.
    Hale ME; Zimmerman TR; Ma Y; Malamut R
    J Opioid Manag; 2015; 11(5):425-34. PubMed ID: 26535970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydrocodone Bitartrate ER (Hysingla
    Dhillon S
    Clin Drug Investig; 2016 Nov; 36(11):969-980. PubMed ID: 27718163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between change in pain intensity and functional outcomes in patients with chronic pain receiving twice daily extended-release hydrocodone bitartrate.
    Argoff C; Arnstein P; Stanos S; Robinson CY; Galer BS; Gould E; Gammaitoni A
    J Opioid Manag; 2015; 11(5):417-24. PubMed ID: 26535969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Once-Daily Extended-Release (ER) Hydrocodone in Individuals Previously Receiving ER Morphine for Chronic Pain.
    Broglio K; Pergolizzi J; Kowalski M; Lynch SY; He E; Wen W
    Pain Pract; 2017 Mar; 17(3):382-391. PubMed ID: 27317188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.